- Conditions
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Interventions
- Capivasertib
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1369–1392
of 17,274
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Cancer
- Interventions
- Erlotinib (Tarceva), Intra-arterial Cisplatin (PLAT), Radiation Therapy (RAD)
- Drug · Radiation
- Lead sponsor
- Southern Illinois University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2015
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Recurrent or Persistent Endometrial Carcinoma
- Interventions
- Sodium cridanimod
- Drug
- Lead sponsor
- Kevelt AS
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 4
- States / cities
- San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more
- Conditions
- Non-Hodgkin's Lymphoma, Burkitt Lymphoma, Primary Effusion Lymphomas
- Interventions
- Pegylated Liposomal Doxorubicin (Doxil) and Rituximab
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- HIV Infections, Leukoencephalopathy, Progressive Multifocal
- Interventions
- Filgrastim, Cytarabine, Zidovudine, Zalcitabine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1997
- U.S. locations
- 9
- States / cities
- Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more
- Conditions
- Pain
- Interventions
- GSK3858279, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Surprise, Arizona • Cerritos, California + 15 more
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
- Interventions
- Mogamulizumab, Pembrolizumab
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 8
- States / cities
- Sacramento, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Gastric Cancer, Ovarian Cancer
- Interventions
- navicixizumab+paclitaxel, navicixizumab+irinotecan, navicixizumab monotherapy
- Biological
- Lead sponsor
- OncXerna Theraputics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Hot Springs, Arkansas • Los Angeles, California • Tampa, Florida + 5 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Pentosan Polysulfate Sodium twice weekly, Placebo (Sodium Chloride Injection, 0.9%), Pentosan Polysulfate Sodium Fixed Dose, Pentosan Polysulfate Sodium once weekly
- Drug
- Lead sponsor
- Paradigm Biopharmaceuticals USA (INC)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 602 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 29
- States / cities
- Tempe, Arizona • Tucson, Arizona • Cerritos, California + 20 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773 low dose, Placebo BI 10773 high dose, BI 10773 high dose, Placebo BI 10773 low dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,064 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 170
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 140 more
- Conditions
- Heartburn
- Interventions
- Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg, Lansoprazole, Calcium carbonate/magnesium hydroxide, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Healthy Volunteer
- Interventions
- AVP-786, AVP-923
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
- Interventions
- Daclizumab
- Drug
- Lead sponsor
- Facet Biotech
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 30
- States / cities
- Huntsville, Alabama • Anaheim, California • Los Angeles, California + 24 more
- Conditions
- Glioblastoma, GBM, Glioma
- Interventions
- Trans Sodium Crocetinate (TSC)
- Drug
- Lead sponsor
- Diffusion Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 13 more
- Conditions
- Subcutaneous Fat
- Interventions
- CBL-514 Injection, 0.9 % sodium chloride
- Drug
- Lead sponsor
- Caliway Biopharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Encinitas, California
- Conditions
- Polycythemia Vera (PV)
- Interventions
- DISC-3405
- Drug
- Lead sponsor
- Disc Medicine, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 11 more
- Conditions
- Acute Pain
- Interventions
- VX-150, HB/APAP, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 243 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 4
- States / cities
- Phoenix, Arizona • Anaheim, California • Pasadena, California + 1 more
- Conditions
- Extensive Stage-small Cell Lung Cancer
- Interventions
- Ifinatamab deruxtecan, Atezolizumab, Carboplatin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
- Conditions
- HIV Infections
- Interventions
- lopinavir/ritonavir, emtricitabine, stavudine, tenofovir DF
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 402 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2006
- U.S. locations
- 27
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 20 more
- Conditions
- Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Alveolar Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Interventions
- Elimusertib
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
- Conditions
- PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
- Interventions
- Miransertib
- Drug
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 6
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more
- Conditions
- Kidney Cancer
- Interventions
- dolastatin 10
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2009
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Head and Neck Cancer
- Interventions
- cetuximab, cisplatin, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Sarcoma, Malignant Peripheral Nerve Sheath Tumors
- Interventions
- PLX3397, sirolimus
- Drug
- Lead sponsor
- Gulam Manji
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Boston, Massachusetts • Ann Arbor, Michigan + 2 more